TABLE 1.
Sample Characteristics
| Characteristics | New Users |
Prevalent Users |
||
|---|---|---|---|---|
| Target (n = 679) | Non-Target (n = 4182) | Target (n = 16,421) | Non-Target (n = 105,925) | |
| N (%) | N (%) | N (%) | N (%) | |
| Female | 395 (58.2) | 2263 (54.8) | 10,156 (61.9) | 62,390 (59.8) |
| Mean age | 44.0 (11.7) | 45.9 (11.1) | 57.9 (15.7) | 59.4 (14.9) |
| Diagnosis of | ||||
| Atrial fibrillation | 16 (2.4) | 70 (1.7) | 1353 (8.2) | 9445 (8.9) |
| Asthma | 5 (0.8) | 30 (0.7) | 3135 (19.1) | 21,159 (20.0) |
| CAD | 29 (4.3) | 207 (5.0) | 2811 (17.1) | 20,521 (19.4) |
| Congestive heart failure | 2 (0.3) | 21 (0.5) | 1160 (7.1) | 8938 (8.4) |
| Depression | 293 (43.2) | 1617 (39.1) | 4952 (30.2) | 27,788 (26.2) |
| Diabetes | 54 (8.0) | 280 (6.8) | 3193 (19.4) | 23,609 (22.3) |
| Hypertension | 169 (24.9) | 1154 (27.9) | 11,093 (67.6) | 77,524 (73.2) |
| Hyperlipidemia | 110 (16.2) | 723 (17.5) | 6365 (38.8) | 40,866 (38.6) |
| Osteoporosis | 24 (3.5) | 206 (5.0) | 1976 (12.0) | 12,351 (11.7) |
| Medication use | ||||
| Calcium channel blockers | 12 (1.8) | 91 (2.2) | 739 (4.5) | 5210 (4.9) |
| Warfarin | 7 (1.0) | 32 (0.8) | 314 (1.9) | 2031 (1.9) |
| Digoxin | 0 (0) | 0 (0) | 110 (0.7) | 795 (0.8) |
| Diabetes | 45 (6.6) | 214 (5.2) | 709 (4.3) | 5085 (4.8) |
| Inhaled steroids | 5 (0.7) | 28 (0.7) | 493 (3.0) | 3079 (2.9) |
| Bisphosphonates | 24 (3.5) | 206 (5.0) | 806 (4.9) | 4931 (4.7) |
| Antiplatelet | 0 (0) | 0 (0) | 102 (0.6) | 791 (0.8) |
| Leukotriene modifiers | 0 (0) | 2 (0.1) | 145 (0.9) | 909 (0.9) |
| Antidepressant | 293 (43.2) | 1617 (39.1) | 3429 (20.9) | 18,352 (17.3) |
| Beta blocker | 90 (13.3) | 574 (13.9) | 2432 (14.8) | 16,562 (15.6) |
| ACE/ARB | 88 (13.0) | 607 (14.7) | 2326 (14.2) | 15,954 (15.1) |
| Statin | 115 (16.9) | 761 (18.4) | 1722 (10.5) | 11,534 (10.9) |
| Healthcare utilization | ||||
| Mean no. unique medications (SD) | 2.4 (2.1) | 2.3 (1.7) | 5.1 (4.7) | 5.2 (4.9) |